10515194|t|Cerebrospinal fluid levels of amyloid beta-peptide1-42, but not tau have positive correlation with brain glucose metabolism in humans.
10515194|a|To address the question of whether assay for cerebrospinal fluid (CSF) levels of amyloid beta-peptide 1-42 (A(beta)1-42) and tau allow us to monitor the neurodegenerative processes that lead to a progressive and massive death of neurons in Alzheimer's disease (AD) and non-AD patients, cerebral glucose metabolism using 2-[18F] fluoro-2-deoxy-glucose was quantified by positron emission tomography in fifteen AD patients and nine non-AD patients with defined levels of CSF-A(beta)1-42 and CSF-tau. The CSF-A(beta)1-42 levels, but not the CSF-tau levels, in both AD and non-AD patients consistently and significantly correlated with global and, in particular, temporal lobe glucose metabolism. Results from our study suggest that the CSF-A(beta)1-42 levels may reflect residual brain function and help monitoring progression of dementing disorders.
10515194	64	67	tau	Gene	4137
10515194	105	112	glucose	Chemical	MESH:D005947
10515194	127	133	humans	Species	9606
10515194	260	263	tau	Gene	4137
10515194	375	394	Alzheimer's disease	Disease	MESH:D000544
10515194	396	398	AD	Disease	MESH:D000544
10515194	408	410	AD	Disease	MESH:D000544
10515194	411	419	patients	Species	9606
10515194	430	437	glucose	Chemical	MESH:D005947
10515194	455	485	2-[18F] fluoro-2-deoxy-glucose	Chemical	-
10515194	544	546	AD	Disease	MESH:D000544
10515194	547	555	patients	Species	9606
10515194	569	571	AD	Disease	MESH:D000544
10515194	572	580	patients	Species	9606
10515194	628	631	tau	Gene	4137
10515194	676	680	-tau	Gene	4137
10515194	697	699	AD	Disease	MESH:D000544
10515194	708	710	AD	Disease	MESH:D000544
10515194	711	719	patients	Species	9606
10515194	808	815	glucose	Chemical	MESH:D005947
10515194	962	981	dementing disorders	Disease	MESH:D009358
10515194	Association	MESH:D005947	MESH:D000544

